These dividend stocks are cheap and have high payout growth, says Wolfe

Wolfe Research highlights dividend aristocrats as a potentially inexpensive, income-oriented defensive strategy, noting the cohort's relative PE vs. the S&P 500 at ~0.83x and an aggregate dividend yield of ~2.5%. The firm screened 30 aristocrats for high dividend growth or second‑quintile yields and cites examples: Becton Dickinson (2.19% yield, -16% YTD, Q4 EPS beat but revenue miss; activist Starboard involvement; 3.7% analyst upside), Abbott Laboratories (1.84% yield, +11% YTD, disappointing Q3 results but analysts see 15.4% upside; agreed to buy Exact Sciences for up to $23bn, close expected Q2 2026) and General Dynamics (1.81% yield, +27% YTD, raised FY guidance and beat Q3; 14.5% analyst upside).

Analysis

Market structure: Dividend Aristocrats (NOBL) trade at a relative PE of ~0.83x vs. the S&P with a ~2.5% yield, signaling a buyer base for defensive income names (staples, industrials, financials) and pressure on high-PE growth/tech. Direct winners: GD (backlog + earnings beats) and cash-generative healthcare names (ABT) that can deploy buybacks/M&A; losers: richly valued growth names if rotation into dividends persists. Cross-asset: a durable move into dividends would tighten corporate bond spreads for higher-quality issuers but raise downside gamma in equity options for growth names and modestly strengthen USD if yields reprice.

Risk assessment: Tail risks include ABT/EXAS integration failing or antitrust delays (deal closes expected by Q2 2026), defense budget swings hitting GD, and activist-driven breakups (BDX/Starboard) creating one-off volatility. Time horizons: immediate (days) for earnings/guide reactions, short-term (weeks–6 months) for re-rating of NOBL relative PE toward historical ~0.95x, long-term (quarters–years) for dividend growth compounding. Hidden dependencies: dividend sustainability tied to FCF/pension funding and M&A financing method; catalysts include Fed rate moves, macro growth reacceleration, and M&A rulings.

Trade implications: Favor selective longs in GD (operational beat + 14.5% analyst upside) and NOBL ETF for a 3–12 month mean-reversion trade; use capital-efficient option structures to cap downside. Construct pair trades: long ABT (event-driven around EXAS integration) vs. short a high-PE healthcare/diagnostics pure-play (EXAS) to hedge execution risk. Options: buy 9–15 month LEAP calls on GD funded by selling 3–6 month OTM calls; for ABT, use a buy-write or calendar spread to monetize time decay pre-close.

Contrarian angles: Consensus discounts dividend aristocrats as “defensive” but underprices their buyback/leverage optionality if rates fall—historical parallels (2012–2013) show ~10–20% re-rating within 6–12 months on yield compression. Overdone risks: if yields rise >50bp in 3 months, defensive names underperform materially; monitor quick triggers (dividend payout ratio >65%, net debt/EBITDA increase >0.5x, or GD backlog growth <5% YoY) that would invalidate the trade.

Key Decisions for Investors

• Establish a 2–3% long position in GD (General Dynamics) via stock or a 12‑month call spread (buy 2026 LEAP, sell nearer-dated call) targeting ~14–20% upside; set stop-loss at -12% or if backlog growth drops below 5% YoY.
• Buy a 2% position in NOBL (ProShares S&P 500 Dividend Aristocrats ETF) as a 3–12 month mean-reversion/dividend capture trade; hedge with a 1% short position in QQQ or buy a 3‑month 5–7% OTM put on NOBL if Fed rate hikes >50bp occur in 60 days.
• Initiate a 1–2% event-driven long in ABT (Abbott) funded by selling 3–6 month OTM calls: target 10–25% upside on successful EXAS integration by Q2 2026; exit or reduce if regulatory clearance is delayed beyond Q2 2026 or net debt/EBITDA increases >0.5x.
• Avoid initiating larger positions in BDX until Starboard’s proposals and any divestiture timeline are clarified; consider a 0.5–1% short or put position if activist-driven sell-off stalls operational fixes after two consecutive quarters without margin improvement.